Please note: AABB reserves the right to make updates to this program.
Wednesday, December 5, 2018
2:00 – 3:30 PM (ET) 7:00 – 8:30 PM (GMT)
Master Program Number: 18EL-385 (see program format numbers below under Registration)
Educational Track: Technical/Clinical
Topic: Transfusion Medicine
Intended Audience: CEOs, Director, Hospitals, Hospital Blood Banks, Managers/Supervisors, Medical Director, Physicians, Resident/Fellow, Scientist, Students (MD, MT, SBB), Transfusion Safety Officer
Teaching Level: Intermediate to Advanced
Director/Moderator: Eric A. Gehrie, MD, Assistant Professor, Pathology, Johns Hopkins University, Baltimore, MD
Speakers: To be Announced
After participating in this educational activity, participants should be able to:
- Discuss the risks posed to patients by bacteria in platelet components.
- Appreciate the various technologies that can help to detect bacterial contamination of platelet concentrates.
- Identify regulatory guidance regarding the implementation of technologies intended to limit the exposure of transfusion recipients to platelets contaminated with platelets.
- Have an action plan for compliance with regulatory requirements.
For many years, bacterial contamination of platelets has been a major medical and regulatory concern. With the FDA approval of several different platforms (pathogen reduction technology, time of issue bacterial testing, etc.) that could be used to detect and/or limit exposure of patients to platelets contaminated with bacteria, the transfusion community is anticipating additional regulatory action/requirements. Once final regulatory action has taken place, this program will seek to explain the significance of the action and outline ways for collection centers and hospital transfusion services to comply.
| || ||
|Single Viewer: Live||
|Single Viewer: On-Demand||
|Group Viewing: Live||
|Group Viewing: On-Demand||
|Group Viewing: Live & On-Demand||